The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ErrataFull Access

Erratum

Published Online:https://doi.org/10.1176/pn.44.9.0013

• In the April 17 issue, the professional title of Anand Pandya, M.D., was stated incorrectly in the article titled “Consortium Tells Congress Why It's Crucial to Boost MH Funds” and the accompanying photo caption. His correct title is vice chair of psychiatry at Cedars-Sinai Medical Center in Los Angeles. Pandya is also president of the National Alliance on Mental Illness.

• The article in the March 20 issue titled “Medical Marijuana Verdict Elusive Despite Study, Debate” stated that “the American College of Physicians [ACP], among other groups, has called for reclassification of marijuana under the Controlled Substances Act from a Schedule I drug—under which it is deemed to have high abuse potential and no proven medical uses—to another schedule that would make it more available to researchers and clinicians.”

In fact, in January 2008 the ACP Board of Regents did approve a resolution that read as follows: “ACP urges review of marijuana status as a Schedule I controlled substance and reclassification into a more appropriate schedule, given the scientific evidence regarding marijuana's safety and efficacy in some clinical conditions.” However, in response to questions that were raised about the intent of that resolution, the Regents in April 2008 approved a revised resolution in which it urged “an evidence-based review of marijuana's status as a Schedule I controlled substance to determine whether it should be reclassified to a different schedule.” The revised position added that “this review should consider the scientific findings regarding marijuana's safety and efficacy in some clinical conditions as well as evidence on the health risks associated with marijuana consumption, particularly in its crude smoked form.” ▪